Effect of Benfotiamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy

被引：40

作者：

Alkhalaf, Alaa ^{[1
,2
,3
]}

Kleefstra, Nanne ^{[1
,2
,4
]}

Groenier, Klaas H. ^{[2
,5
]}

Bilo, Henk J. G. ^{[1
,2
,3
]}

Gans, Reinold O. B. ^{[1
]}

Heeringa, Peter ^{[6
]}

Scheijen, Jean L. ^{[7
]}

Schalkwijk, Casper G. ^{[7
]}

Navis, Gerjan J. ^{[1
]}

Bakker, Stephan J. L. ^{[1
]}

机构：

[1] Univ Groningen, Dept Internal Med, Univ Med Ctr Groningen, Groningen, Netherlands

[2] Isala Clin, Ctr Diabet, Zwolle, Netherlands

[3] Isala Clin, Dept Internal Med, Zwolle, Netherlands

[4] Langerhans Med Res Grp, Zwolle, Netherlands

[5] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands

[6] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands

[7] Univ Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands

来源：

PLOS ONE | 2012年 / 7卷 / 07期

关键词：

HUMAN PLASMA-PROTEIN; HIGH-DOSE THIAMINE; VASCULAR-DISEASE; DOUBLE-BLIND; CELLS;

D O I：

10.1371/journal.pone.0040427

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on markers of these pathways in patients with type 2 diabetes and nephropathy. Methods: Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43). Plasma and urinary AGEs (N-epsilon-( carboxymethyl) lysine [CML], N-epsilon-(Carboxyethyl) lysine [CEL], and 5- hydro- 5- methylimidazolone [MG- H1]) and plasma markers of endothelial dysfunction (soluble vascular cell adhesion molecule-1 [sVCAM-1], soluble intercellular adhesion molecule- 1 [sICAM-1], soluble E-selectin) and low-grade inflammation (high-sensitivity C-reactive protein [hs-CRP], serum amyloid-A [SAA], myeloperoxidase [MPO]) were measured at baseline and after 6 and 12 weeks. Results: Compared to placebo, benfotiamine did not result in significant reductions in plasma or urinary AGEs or plasma markers of endothelial dysfunction and low-grade inflammation. Conclusions: Benfotiamine for 12 weeks did not significantly affect intermediate pathways of hyperglycemia-induced vascular complications.

引用

页数：6

共 16 条

[1] A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy [J].